Sarepta Stock Performance

News

FDA, Gene Therapy and Sarepta

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD).

· 2h

FDA Places Sarepta's Investigational Gene-Therapy Trials on Hold Following Patient Death

· 2d

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths

21m

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

Beware of SBET, WeBull, and Sarepta

Investors who bought WeBull (BULL) before last week gained 33.6%. However, after the market closed on Friday, July 18, the ...

Sarepta: Finally, A Little Relief For Bulls; I Expect More

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Business Insider6mon

Sarepta Therapeutics: A Buy Rating Backed by Strong Elevidys ...

In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00.

Benzinga.com1mon

Latest Sarepta Therapeutics Stock News | NASDAQ:SRPT | Benzinga

Get the latest news on Sarepta Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SRPT performance ...

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Nasdaq7mon

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? - Nasdaq

The surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Elevidys – A Key Driver of Sarepta’s Top line ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results